BillionToOne Faces Short Report Alleging Kickbacks, Flawed Diagnostic Tests
Short seller Fuzzy Panda accuses BillionToOne of undisclosed Medicaid fraud, illegal kickbacks, and flawed tests in a scathing new report.
Follow the latest Elevance Health, Inc. (ELV) news and market headlines alongside the live ELV price. Stay informed on what's moving ELV.
Short seller Fuzzy Panda accuses BillionToOne of undisclosed Medicaid fraud, illegal kickbacks, and flawed tests in a scathing new report.
Wall Street analysts upgraded TIGO, MWH, CNX, TNDM and ELV, with mixed price-target changes.
Argus Research analyst David Toung upgrades Elevance Health (NYSE:ELV) from Hold to Buy and announces $510 price target.
Federal regulators propose sweeping Medicare, Medicaid, and Marketplace anti-fraud reforms projected to save taxpayers nearly $90 billion.
The Centers for Medicare & Medicaid Services (CMS) today issued a proposed rule that could save taxpayers nearly $90 billion over the next 10 years and would strengthen program integrity (PI) oversight and the
The Centers for Medicare & Medicaid Services (CMS) today issued a proposed rule that could save taxpayers nearly $90 billion over the next 10 years and would strengthen program integrity (PI) oversight and the
A look at the portfolio changes for Baupost Group from Q2 to Q3 and the new stocks Seth Klarman is betting on.
Humana Inc. has launched a new oncology care model in partnership with Evolent Health and American Oncology Network across eight states. The initiative streamlines prior authorization for qualifying practices, uses EHR analytics and provider scorecards to promote evidence-based cancer treatment, and aims to improve care coordination while reducing specialty care spending. HUM stock has rallied 82.2% over the past year but trades at a premium valuation of 29.08x forward P/E versus the industry average of 15.72x.
In a comparison of two Medical Services stocks, Elevance Health (ELV) and Revvity (RVTY), both holding a Zacks Rank #2 (Buy), ELV emerges as the superior value option. ELV features a lower forward P/E ratio of 14.97 compared to RVTY's 29.34, a better PEG ratio of 2.08 versus 2.79, and a lower P/B ratio of 2.07 versus 2.44. These metrics contribute to ELV's Value grade of A compared to RVTY's C grade.
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to ELV, including RealStocks and Stock Futures.
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.